Serum markers for predicting pre-eclampsia

Molecular Aspects of Medicine

Volumn 28, Issue 2, 2007, Pages 227-244

  Baumann, Marc U ^a   Bersinger, Nick A ^a   Surbek, Daniel V ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Pre eclampsia; Serum markers; Sonography

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; PLACENTAL PROTEIN 13; UNCLASSIFIED DRUG;

DOPPLER ECHOGRAPHY; ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; MORBIDITY; MORTALITY; PERINATAL PERIOD; PREECLAMPSIA; PREGNANCY; REVIEW; SCREENING;

ANTIGENS, CD; BIOLOGICAL MARKERS; FEMALE; GALECTINS; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; ULTRASONOGRAPHY, PRENATAL;

EID: 34249739102     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2007.04.002     Document Type: Review

References (97)

1. Al-Mufti R., Hambley H., Albaiges G., et al. Increased fetal erythroblasts in women who subsequently develop pre-eclampsia. Hum. Reprod. 15 (2000) 1624-1628
2. Anim-Nyame N., Sooranna S.R., Steer P.J., et al. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and pre-eclampsia. Hum. Reprod. 15 (2000) 2033-2036
3. Anim-Nyame N., Hills F.A., Sooranna S.R., et al. A longitudinal study of maternal plasma insulin-like growth factor binding protein-1 concentrations during normal pregnancy and pregnancies complicated by pre-eclampsia. Hum. Reprod. 15 (2000) 2215-2219
4. Aquilina J., Thompson O., Thilaganathan B., et al. Improved early prediction of pre-eclampsia by combining second-trimester maternal serum inhibin-A and uterine artery Doppler. Ultrasound Obstet. Gynecol. 17 (2001) 477-484
5. Ashour A.M., Lieberman E.S., Haug L.E., et al. The value of elevated second-trimester beta-human chorionic gonadotropin in predicting development of preeclampsia. Am. J. Obstet. Gynecol. 176 (1997) 438-442
6. Audibert F., Benchimol Y., Benattar C., et al. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. Fetal Diagn. Ther. 20 (2005) 48-53
7. Autiero M., Luttun A., Tjwa M., et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J. Thromb. Haemost. 1 (2003) 1356-1370
8. Bandivdekar A.H., Varadkar A.M., and Sheth A.R. Endocrine control of inhibin biosynthesis by human placenta. Biol. Res. Pregnancy Perinatol. 6 (1985) 128-132
9. Bersinger N.A., and Odegard R.A. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet. Gynecol. Scand. 83 (2004) 37-45
10. Bersinger N.A., and Odegard R.A. Serum levels of macrophage colony stimulating, vascular endothelial, and placenta growth factor in relation to later clinical onset of pre-eclampsia and a small-for-gestational age birth. Am. J. Reprod. Immunol. 54 (2005) 77-83
11. Bersinger N.A., Smarason A.K., Muttukrishna S., et al. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens. Pregnancy 22 (2003) 45-55
12. Bersinger N.A., and Odegard R.A. Early biochemical detection of pre-eclampsia: the role of placental proteins. Immunoanal. Biol. Spec. 19 (2004) 47-53
13. Burger O., Pick E., Zwickel J., et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 25 (2004) 608-622
14. Byrne B.M., Crowley A., Taulo F., et al. Fetal DNA quantitation in peripheral blood is not useful as a marker of disease severity in women with preeclampsia. Hypertens. Pregnancy 22 (2003) 157-164
15. Caritis S., Sibai B., Hauth J., et al. Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am. J. Obstet. Gynecol. 179 (1998) 946-951
16. Chaiworapongsa T., Romero R., Espinoza J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190 (2004) 1541-1547 discussion 1547-1550, 2004
17. Chappell L.C., Seed P.T., Briley A., et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am. J. Obstet. Gynecol. 187 (2002) 127-136
18. Chien P.F., Arnott N., Gordon A., et al. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 107 (2000) 196-208
19. Clark D.E., Smith S.K., He Y., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol. Reprod. 59 (1998) 1540-1548
20. Clifton V.L., Crompton R., Smith R., et al. Microvascular effects of CRH in human skin vary in relation to gender. J. Clin. Endocrinol. Metab. 87 (2002) 267-270
21. Conde-Agudelo A., Villar J., and Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet. Gynecol. 104 (2004) 1367-1391
22. Cotter A.M., Molloy A.M., Scott J.M., et al. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of nonsevere preeclampsia. Am. J. Obstet. Gynecol. 189 (2003) 391-394 discussion 394-396
23. Crosignani P.G., Trojsi L., Attanasio A.E., et al. Value of HCG and HCS measurement in clinical practice. Obstet. Gynecol. 44 (1974) 673-681
24. D'Anna R., Baviera G., Corrado F., et al. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet. Gynecol. Scand. 83 (2004) 155-158
25. Farese S., Shojaati K., Kadereit B., et al. Blood pressure reduction in pregnancy by sodium chloride. Nephrol. Dial. Transplant. 21 (2006) 1984-1987
26. Florio P., Severi F.M., Ciarmela P., et al. Placental stress factors and maternal-fetal adaptive response: the corticotropin-releasing factor family. Endocrine 19 (2002) 91-102
27. Florio P., Imperatore A., Sanseverino F., et al. The measurement of maternal plasma corticotropin-releasing factor (CRF) and CRF-binding protein improves the early prediction of preeclampsia. J. Clin. Endocrinol. Metab. 89 (2004) 4673-4677
28. Fraser II R.F., McAsey M.E., and Coney P. Inhibin-A and pro-alpha C are elevated in preeclamptic pregnancy and correlate with human chorionic gonadotropin. Am. J. Reprod. Immunol. 40 (1998) 37-42
29. Giudice L.C., Conover C.A., Bale L., et al. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J. Clin. Endocrinol. Metab. 87 (2002) 2359-2366
30. Goffinet F., Aboulker D., Paris-Llado J., et al. Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. BJOG 108 (2001) 510-518
31. Hafner E., Metzenbauer M., Hofinger D., et al. Comparison between three-dimensional placental volume at 12 weeks and uterine artery impedance/notching at 22 weeks in screening for pregnancy-induced hypertension, pre-eclampsia and fetal growth restriction in a low-risk population. Ultrasound Obstet. Gynecol. 27 (2006) 652-657
32. Hanisch C.G., Pfeiffer K.A., Schlebusch H., et al. Adhesion molecules, activin and inhibin - candidates for the biochemical prediction of hypertensive diseases in pregnancy?. Arch. Gynecol. Obstet. 270 (2004) 110-115
33. Higgins J.R., Walshe J.J., Halligan A., et al. Can 24-h ambulatory blood pressure measurement predict the development of hypertension in primigravidae?. Br. J. Obstet. Gynaecol. 104 (1997) 356-362
34. Holden D.P., Fickling S.A., Whitley G.S., et al. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am. J. Obstet. Gynecol. 178 (1998) 551-556
35. Holzgreve W., Ghezzi F., Di Naro E., et al. Disturbed feto-maternal cell traffic in preeclampsia. Obstet. Gynecol. 91 (1998) 669-672
36. Holzgreve W., Li J.J., Steinborn A., et al. Elevation in erythroblast count in maternal blood before the onset of preeclampsia. Am. J. Obstet. Gynecol. 184 (2001) 165-168
37. Irwin J.C., and Giudice L.C. Insulin-like growth factor binding protein-1 binds to placental cytotrophoblast alpha5beta1 integrin and inhibits cytotrophoblast invasion into decidualized endometrial stromal cultures. Growth Horm. IGF Res. 8 (1998) 21-31
38. Irwin J.C., Suen L.F., Faessen G.H., et al. Insulin-like growth factor (IGF)-II inhibition of endometrial stromal cell tissue inhibitor of metalloproteinase-3 and IGF-binding protein-1 suggests paracrine interactions at the decidua:trophoblast interface during human implantation. J. Clin. Endocrinol. Metab. 86 (2001) 2060-2064
39. Kielstein J.T., Impraim B., Simmel S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-177
40. Kyle P.M., Buckley D., Kissane J., et al. The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. Am. J. Obstet. Gynecol. 173 (1995) 865-872
41. Laursen L.S., Overgaard M.T., Soe R., et al. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF. implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett. 504 (2001) 36-40
42. Leung T.N., Chung T.K., Madsen G., et al. Analysis of mid-trimester corticotrophin-releasing hormone and alpha-fetoprotein concentrations for predicting pre-eclampsia. Hum. Reprod. 15 (2000) 1813-1818
43. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350 (2004) 672-683
44. Levine R.J., Qian C., Leshane E.S., et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am. J. Obstet. Gynecol. 190 (2004) 707-713
45. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355 (2006) 992-1005
46. Lo Y.M., Leung T.N., Tein M.S., et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin. Chem. 45 (1999) 184-188
47. Martinez-Abundis E., Gonzalez-Ortiz M., and Pascoe-Gonzalez S. Serum leptin levels and the severity of preeclampsia. Arch. Gynecol. Obstet. 264 (2000) 71-73
48. Maynard S.E., Venkatesha S., Thadhani R., et al. Soluble fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr. Res. 57 (2005) 1R-7R
49. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 329 (1993) 2002-2012
50. Muller F., Savey L., Le Fiblec B., et al. Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. Am. J. Obstet. Gynecol. 175 (1996) 37-40
51. Muller P.R., James A.H., Murtha A.P., et al. Circulating angiogenic factors and abnormal uterine artery Doppler velocimetry in the second trimester. Hypertens. Pregnancy 25 (2006) 183-192
52. Murphy M.M., Scott J.M., McPartlin J.M., et al. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study. Am. J. Clin. Nutr. 76 (2002) 614-619
53. Muttukrishna S., Knight P.G., Groome N.P., et al. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 349 (1997) 1285-1288
54. Muttukrishna S., North R.A., Morris J., et al. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum. Reprod. 15 (2000) 1640-1645
55. Nicolaides K.H., Bindra R., Turan O.M., et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet. Gynecol. 27 (2006) 13-17
56. Ning Y., Williams M.A., Vadachkoria S., et al. Maternal plasma concentrations of insulinlike growth factor-1 and insulinlike growth factor-binding protein-1 in early pregnancy and subsequent risk of preeclampsia. Clin. Biochem. 37 (2004) 968-973
57. Onalan R., Onalan G., Gunenc Z., et al. Combining 2nd-trimester maternal serum homocysteine levels and uterine artery Doppler for prediction of preeclampsia and isolated intrauterine growth restriction. Gynecol. Obstet. Invest. 61 (2006) 142-148
58. Ong C.Y., Liao A.W., Cacho A.M., et al. First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction. Obstet. Gynecol. 98 (2001) 608-611
59. Papageorghiou A.T., and Campbell S. First trimester screening for preeclampsia. Curr. Opin. Obstet. Gynecol. 18 (2006) 594-600
60. Perkins A.V., Linton E.A., Eben F., et al. Corticotrophin-releasing hormone and corticotrophin-releasing hormone binding protein in normal and pre-eclamptic human pregnancies. Br. J. Obstet. Gynaecol. 102 (1995) 118-122
61. Petraglia F., Vaughan J., and Vale W. Inhibin and activin modulate the release of gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone from cultured human placental cells. Proc. Natl. Acad. Sci. USA 86 (1989) 5114-5117
62. Petraglia F., Florio P., Benedetto C., et al. High levels of corticotropin-releasing factor (CRF) are inversely correlated with low levels of maternal CRF-binding protein in pregnant women with pregnancy-induced hypertension. J. Clin. Endocrinol. Metab. 81 (1996) 852-856
63. Polliotti B.M., Fry A.G., Saller D.N., et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet. Gynecol. 101 (2003) 1266-1274
64. Poston L., Briley A.L., Seed P.T., et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367 (2006) 1145-1154
65. Red-Horse K., Zhou Y., Genbacev O., et al. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J. Clin. Invest. 114 (2004) 744-754
66. Redman C.W., and Sargent I.L. Latest advances in understanding preeclampsia. Science 308 (2005) 1592-1594
67. Salomon L.J., Benattar C., Audibert F., et al. Severe preeclampsia is associated with high inhibin A levels and normal leptin levels at 7 to 13 weeks into pregnancy. Am. J. Obstet. Gynecol. 189 (2003) 1517-1522
68. Sargent I.L., Germain S.J., Sacks G.P., et al. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J. Reprod. Immunol. 59 (2003) 153-160
69. Savvidou M.D., Hingorani A.D., Tsikas D., et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361 (2003) 1511-1517
70. Savvidou M.D., Yu C.K., Harland L.C., et al. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am. J. Obstet. Gynecol. 195 (2006) 1668-1673
71. Shibata E., Rajakumar A., Powers R.W., et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J. Clin. Endocrinol. Metab. 90 (2005) 4895-4903
72. Shojaati K., Causevic M., Kadereit B., et al. Evidence for compromised aldosterone synthase enzyme activity in preeclampsia. Kidney Int. 66 (2004) 2322-2328
73. Sibai B.M., Mercer B., and Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am. J. Obstet. Gynecol. 165 (1991) 1408-1412
74. Sibai B., Dekker G., and Kupferminc M. Pre-eclampsia. Lancet 365 (2005) 785-799
75. Smith G.C., Pell J.P., and Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 357 (2001) 2002-2006
76. Smith G.C., Stenhouse E.J., Crossley J.A., et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J. Clin. Endocrinol. Metab. 87 (2002) 1762-1767
77. Spencer K., Yu C.K., Cowans N.J., et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat. Diagn. 25 (2005) 949-953
78. Spencer K., Yu C.K., Savvidou M., et al. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet. Gynecol. 27 (2006) 658-663
79. Spencer K., Cowans N.J., Chefetz I., et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet. Gynecol. (2006)
80. Subtil D., Goeusse P., Houfflin-Debarge V., et al. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 2). BJOG 110 (2003) 485-491
81. Talledo O.E. Renin-angiotensin system in normal and toxemic pregnancies. I. Angiotensin infusion test. Am. J. Obstet. Gynecol. 96 (1966) 141-143
82. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J. Clin. Endocrinol. Metab. 89 (2004) 770-775
83. Toop K., and Klopper A. Concentration of pregnancy-associated plasma protein A (PAPP-A) in patients with pre-eclamptic toxaemia. Placenta Suppl. 3 (1981) 167-173
84. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12 (2006) 642-649
85. Wald N.J., Morris J.K., Ibison J., et al. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat. Diagn. 26 (2006) 559-564
86. Walker J.J. Pre-eclampsia. Lancet 356 (2000) 1260-1265
87. Weigle D.S., Duell P.B., Connor W.E., et al. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J. Clin. Endocrinol. Metab. 82 (1997) 561-565
88. Williams M.A., Havel P.J., Schwartz M.W., et al. Pre-eclampsia disrupts the normal relationship between serum leptin concentrations and adiposity in pregnant women. Paediatr. Perinat. Epidemiol. 13 (1999) 190-204
89. Wolf M., Hubel C.A., Lam C., et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J. Clin. Endocrinol. Metab. 89 (2004) 6239-6243
90. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
91. Yu J., Shao L.E., Frigon Jr. N.L., et al. : Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid. Immunology 88 (1996) 368-374
92. Yu C.K., Papageorghiou A.T., Parra M., et al. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet. Gynecol. 22 (2003) 233-239
93. Yu C.K., Lakasing L., Papageorghiou A.T., et al. Uterine artery Doppler and mid-trimester maternal plasma homocysteine in subsequent pre-eclampsia. J. Matern. Fetal Neonatal Med. 16 (2004) 134-139
94. Zhong X.Y., Holzgreve W., and Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens. Pregnancy 21 (2002) 77-83
95. Zhou Y., Fisher S.J., Janatpour M., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. J. Clin. Invest. 99 (1997) 2139-2151
96. Zhou Y., McMaster M., Woo K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol. 160 (2002) 1405-1423
97. Zwahlen M., Gerber S., and Bersinger N.A. First trimester markers for pre-eclampsia: placental vs. non-placental protein serum levels. Gynecol. Obstet. Invest. 63 (2006) 15-21